IIUM Repository

Transdermal Buprenorphine: utilization trends in United Kingdom primary care practices

Zin, Che Suraya (2012) Transdermal Buprenorphine: utilization trends in United Kingdom primary care practices. In: FIP Centennial Congress, 3-8 October 2012, Amsterdam, Netherlands.

[img] PDF (Transdermal Buprenorphine: Utilization Trends in United Kingdom Primary Care Practices) - Published Version
Restricted to Repository staff only

Download (864kB) | Request a copy


Background information: The utilization of transdermal buprenorphine rapidly increased in the past 10 years, since the first item launched in 2002. The increase utilization was suggested mainly causing by expending use for chronic pain control. Aims: This preliminary study assessed the utilization trend of both low (5, 10 or 20 μg/hour for 7 days) and high (35, 52.5 or 70 μg/hour for 4 days) dose of transdermal buprenorphine to explore the leading use items. Methods: This cross sectional study was conducted from 2002 to 2010 using the UK Clinical Practice Research Datalink which consists of primary care data from 639 practices. Transdermal buprenorphine prescriptions were extracted using specific product codes. Total and annual numbers of prescriptions were stratified by transdermal formulation doses and analyzed by simple linear regression. Result: 339772 transdermal buprenorphine prescriptions were prescribed for 97035 patients from 2002 to 2010. Of these 81% (n=274613) and 19% (n=65159) of the prescriptions were prescribed for low- and high-dose formulations respectively. Transdermal buprenorphine 5 μg/h (34%) was the most frequently prescribed item followed by 10 μg/h (31%), 20 μg/h (16%), 35 μg/h (9%), 52.5 μg/h (5%) and 70 μg/h (5%). Annual number of prescriptions for all transdermal items significantly increased (11543%) during study period (P<0.001). Conclusion: Low-doses (5 μg/h and 10 μg/h) transdermal buprenorphine were the most frequently prescribed and significantly contributed to the overall increased utilization of transdermal buprenorphine. Further research is required to analyze treatment indications and factors influence prescribing decisions.

Item Type: Conference or Workshop Item (Speech/Talk)
Additional Information: 4127/35827
Subjects: R Medicine > RS Pharmacy and materia medica
Kulliyyahs/Centres/Divisions/Institutes (Can select more than one option. Press CONTROL button): Kulliyyah of Pharmacy > Department of Pharmacy Practice
Depositing User: Prof Dr Che Suraya Mohd Zin
Date Deposited: 10 Mar 2014 09:46
Last Modified: 10 Mar 2014 09:46
URI: http://irep.iium.edu.my/id/eprint/35827

Actions (login required)

View Item View Item


Downloads per month over past year